The Oxford/AstraZeneca COVID-19 vaccine candidate’s late-stage trial outcomes are “intriguing” and extra work must be accomplished on the discovering that an preliminary half dose of the shot presents extra safety, Oxford’s vaccine chief stated on Monday.
Phase III trial results of the vaccine candidate discovered it was 90% efficient if administered at a half dose after which at a full dose, or 62% efficient if administered in two full doses.
“That 90% is an intriguing result. So when we give a half dose as the first dose (it) means that we’ve got more vaccine available. And then… after the second dose we see 90% protection,” Andrew Pollard, director of the Oxford Vaccine Group, informed BBC TV.
“I think that’s a really exciting and intriguing result which we need to dig further into,” he stated.
(Except for the headline, this story has not been edited by NDTV employees and is printed from a syndicated feed.)